Media365
Under the agreement announced on Monday, US-headquartered, Hong Kong-listed Insilico will receive an upfront payment of US$115 million. The deal could have a total value of around US$2.75 billion tied to development, regulatory and commercial milestones, plus tiered royalties on future sales.
The drugs and their disease areas were not disclosed due to contract restrictions. However, Alex Zhavoronkov, the founder and CEO of 12-year-old Insilico, said that “some of those broad-spectrum, multi-target, multi-disease drugs may have been part of this deal”.
He said Insilico had been developing several drugs targeting fibrosis, inflammatory, oncology and other age-related pathways into clinical-stage development.
“These assets could also be applied to oncology, cardiovascular and other disease areas,” Zhavoronkov said.
The announcement described the compounds as “potentially best-in-class, novel oral therapeutics in preclinical development”. The deal will give US pharmaceutical giant Lilly exclusive global rights for their development, manufacturing and commercialisation.
